GFM2

Across TCGA pan-cancer cohorts, GFM2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of GFM2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where GFM2 RNA is repressed in tumor relative to normal tissue. In most cancer types GFM2 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, BLCA, and LUAD are the cancer types where GFM2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GFM2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.574	<.001	9	view →
BLCA	All	III,IV	+0.622	<.001	7	view →
LUAD	Male	All	+0.485	<.001	7	view →
LIHC	Male	All	+0.672	<.001	6	view →
BRCA	All	III,IV	+0.567	<.001	6	view →
STAD	All	II,III,IV	+0.389	.015	4	view →
LUSC	Male	All	+0.370	<.001	4	view →
KIRC	Male	II,III,IV	−0.297	.032	4	view →
KIRP	Male	All	−0.416	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

GFM2–THCA

Open the THCA breakdown →